Balaban D H, Duckworth C W, Peura D A
Division of Gastroenterology and Hepatology, University of Virginia, Charlottesville, USA.
Am J Gastroenterol. 1997 Jan;92(1):79-83.
The efficacy of omeprazole administered by the nasogastric route has not been adequately studied. We sought to determine whether nasogastrically administered omeprazole could effectively maintain an intragastric pH greater than 4.0 in patients hospitalized in a medical intensive care unit.
Patients were considered eligible for the study if they had a nasogastric feeding tube in place and had not received omeprazole, antacids, or histamine-2 blockers in the 5 days preceding study enrollment. Exclusionary criteria included active GI bleeding or a mean baseline gastric pH greater than 4.0. Patients served as their own controls during a 24-h lead-in period, during which baseline intragastric pH was measured by gastric aspirate. Omeprazole, 20 or 40 mg, was administered once daily with water through a nasogastric tube. Intragastric pH was measured every 4-8 h for a maximum of 3 days following drug administration.
Twenty patients were considered eligible for the study; 10 were excluded because of an elevated baseline gastric pH (n = 8) or because proper gastric aspirates could not be obtained (n = 2). The mean baseline intragastric pH in four patients receiving omeprazole 20 mg q.d. was 2.4 +/- 1.1 and increased to 3.7 +/- 1.6 after drug administration (p = 0.013). The mean baseline intragastric pH in six patients receiving omeprazole 40 mg q.d. was 2.8 +/- 0.8 and increased to 5.7 +/- 1.1 after drug administration (p < 0.001). The percentage of intragastric pH values greater than 4.0 after drug administration was 34.2% in patients receiving omeprazole 20 mg q.d. and 84.7% in those receiving omeprazole 40 mg q.d.
Nasogastric omeprazole 40 mg q.d. is effective in maintaining an intragastric pH greater than 4.0 in critically ill patients. The nasogastric administration of omeprazole offers a cost-effective therapeutic option for acid suppression in patients at risk for stress mucosal ulceration.
经鼻胃管途径给予奥美拉唑的疗效尚未得到充分研究。我们试图确定在医学重症监护病房住院的患者中,经鼻胃管给予奥美拉唑是否能有效维持胃内pH值大于4.0。
如果患者有鼻胃饲管且在研究入组前5天未接受过奥美拉唑、抗酸剂或组胺-2受体阻滞剂,则被认为符合研究条件。排除标准包括活动性胃肠道出血或平均基线胃pH值大于4.0。在24小时导入期内,患者作为自身对照,在此期间通过胃抽吸物测量基线胃内pH值。奥美拉唑20毫克或40毫克,每日一次,用水经鼻胃管给药。给药后最多3天内,每4 - 8小时测量一次胃内pH值。
20名患者被认为符合研究条件;10名患者因基线胃pH值升高(n = 8)或无法获得合适的胃抽吸物(n = 2)而被排除。4名每日接受20毫克奥美拉唑的患者的平均基线胃内pH值为2.4±1.1,给药后升至3.7±1.6(p = 0.013)。6名每日接受40毫克奥美拉唑的患者的平均基线胃内pH值为2.8±0.8,给药后升至5.7±1.1(p < 0.001)。每日接受20毫克奥美拉唑的患者给药后胃内pH值大于4.0的百分比为34.2%,每日接受40毫克奥美拉唑的患者为84.7%。
每日经鼻胃管给予40毫克奥美拉唑可有效维持重症患者胃内pH值大于4.0。经鼻胃管给予奥美拉唑为有应激性黏膜溃疡风险的患者提供了一种经济有效的抑酸治疗选择。